New drug immunoglobulin could give three-year reprieve from Alzheimer's

Substance made from antibodies in human blood could be on the shelves in 10 years

Scientists have hailed a new drug for Alzheimer's disease after a trial successfully halted the mental decline associated with the condition for a period of three years.

Researchers found that patients who had injections every two weeks of the drug immunoglobulin, made from antibodies in human blood, showed no decline in cognition, memory, daily functioning or mood.

Immunoglobulin is normally given to patients who suffer from an immune deficiency, but it has also been found to protect the brains of those with early stage Alzheimer's. Each dose is extracted from the plasma of 1,000 blood donors.

Professor Clive Ballard, director of research at the Alzheimer's Society, said: "This is probably the most exciting drug we know about that is currently in the late stages of research.

"We now know it is safe but the real test will be whether these initial promising results can subsequently be replicated in larger groups."

Just 24 patients were tested with the drug in the study, who were given varying doses of the drug over different periods. A larger study is now underway. Professor Ballard added: "If the phase 3 trials are successful, and it can be made cost effective, this drug could be on the shelves within 10 years."

He added: "One in three people over 65 will develop dementia. While finding a cure is the Holy Grail of dementia research, it is also vitally important that we continue to fund studies like this if we are to develop more treatments to help people to live well with the condition."

However, the difficulty of producing immunoglobulin means it is not cheap, costing thousands of pounds per patient. The findings were presented at the Alzheimer's Association International Conference in Vancouver, Canada, yesterday.

There are currently three licensed drugs for the prevention of Alzheimers in the early and moderate stages but they are of limited effectiveness, slowing the progression of the disease in some patients but not in others.

Researchers studying immunoglobulin had previously reported its beneficial effects up to 18 months but have now extended the treatment for a further 18 months and found no decline in cognition and memory.

Scientists have been experimenting with immunotherapy – treatments to stimulate the immune system in Alzheimers patients – for several years but this is the first that has been shown to be both effective and safe.

The drug is thought to work by targeting the beta-amyloid protein, sweeping up and removing small fragments that form the amyloid plaques in the brain that lie behind the degenerative disease.

Normal Relkin, of Weill Cornell Medical College, New York, said: "This is the first study to report long-term stabilisation of Alzheimer's symptoms with intravenous immunoglobulin. While the small number of participants may limit the reliability of our findings , we are very enthusiastic about the results."

Early findings from the trial showed rates of brain shrinkage typical of Alzheimer's were halved in patients treated with the drug, as measured on MRI scans.

Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Chiropractic Assistant

    £16500 per annum: Recruitment Genius: A Chiropractic Assistant is needed in a ...

    Recruitment Genius: Digital Account Executive - Midlands

    £18000 - £26000 per annum: Recruitment Genius: They work with major vehicle ma...

    Recruitment Genius: Web Developer

    £28000 - £30000 per annum: Recruitment Genius: This company provides coaching ...

    Ashdown Group: Front-End UI Application Developer

    £30000 - £40000 per annum + Benefits: Ashdown Group: Front-End UI Application ...

    Day In a Page

    Timeless drama of Championship race in league of its own - Michael Calvin

    Michael Calvin's Last Word

    Timeless drama of Championship race in league of its own
    Where the spooks get their coffee fix: The busiest Starbucks in the US is also the most secretive

    The secret CIA Starbucks

    The coffee shop is deep inside the agency's forested Virginia compound
    Revealed: How the Establishment closed ranks over fallout from Loch Ness Monster 'sighting'

    How the Establishment closed ranks over fallout from Nessie 'sighting'

    The Natural History Museum's chief scientist was dismissed for declaring he had found the monster
    One million Britons using food banks, according to Trussell Trust

    One million Britons using food banks

    Huge surge in number of families dependent on emergency food aid
    Excavation at Italian cafe to fix rising damp unearths 2,500 years of history in 3,000 amazing objects

    2,500 years of history in 3,000 amazing objects

    Excavation at Italian cafe to fix rising damp unearths trove
    The Hubble Space Telescope's amazing journey, 25 years on

    The Hubble Space Telescope's amazing journey 25 years on

    The space telescope was seen as a costly flop on its first release
    Did Conservative peer Lord Ashcroft quit the House of Lords to become a non-dom?

    Did Lord Ashcroft quit the House of Lords to become a non-dom?

    A document seen by The Independent shows that a week after he resigned from the Lords he sold 350,000 shares in an American company - netting him $11.2m
    Apple's ethnic emojis are being used to make racist comments on social media

    Ethnic emojis used in racist comments

    They were intended to promote harmony, but have achieved the opposite
    Sir Kenneth Branagh interview: 'My bones are in the theatre'

    Sir Kenneth Branagh: 'My bones are in the theatre'

    The actor-turned-director’s new company will stage five plays from October – including works by Shakespeare and John Osborne
    The sloth is now the face (and furry body) of three big advertising campaigns

    The sloth is the face of three ad campaigns

    Priya Elan discovers why slow and sleepy wins the race for brands in need of a new image
    How to run a restaurant: As two newbies discovered, there's more to it than good food

    How to run a restaurant

    As two newbies discovered, there's more to it than good food
    Record Store Day: Remembering an era when buying and selling discs were labours of love

    Record Store Day: The vinyl countdown

    For Lois Pryce, working in a record shop was a dream job - until the bean counters ruined it
    Usher, Mary J Blige and Will.i.am to give free concert as part of the Global Poverty Project

    Mary J Blige and Will.i.am to give free concert

    The concert in Washington is part of the Global Citizen project, which aims to encourage young people to donate to charity
    10 best tote bags

    Accessorise with a stylish shopper this spring: 10 best tote bags

    We find carriers with room for all your essentials (and a bit more)
    Paul Scholes column: I hear Manchester City are closing on Pep Guardiola for next summer – but I'd also love to see Jürgen Klopp managing in England

    Paul Scholes column

    I hear Manchester City are closing on Pep Guardiola for next summer – but I'd also love to see Jürgen Klopp managing in England